Cargando…

PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY

Detalles Bibliográficos
Autores principales:	Franklin, Matt, Shupo, Francis, Jones, Emily, Mason, Nicola, Wayi-Wayi, Grace, Kanhai, Karan, Zibelnick, Natasa, Repasky, Mileva, Makarounas-Kirchmann, Kelly, Mukherjee, Sudipto, Brazier, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428897/ http://dx.doi.org/10.1097/01.HS9.0000977504.69432.f9

Ejemplares similares

P911: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY
por: Shupo, F., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

PB2152: THE CLINICAL PICTURE OF CASTLEMAN DISEASE – A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Kanhai, Karan, et al.
Publicado: (2023)

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) AS A MANIFESTATION OF POST-COVID-19 INFLAMMATORY SYNDROME
por: YAN, CHRIS, et al.
Publicado: (2022)

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
por: Rossi, Jean-Francois, et al.
Publicado: (2021)

P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET
por: Mukherjee, S., et al.
Publicado: (2022)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases
por: Korsunska, Ania, et al.
Publicado: (2023)

Genetic basis for iMCD-TAFRO
por: Yoshimi, Akihide, et al.
Publicado: (2020)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

International definition of iMCD-TAFRO: future perspectives
por: Nishimura, Yoshito, et al.
Publicado: (2022)

PB2116: CASTLEMAN’S DISEASE: DIFFERENT CLINICAL BEHAVIOR AND PATHOLOGIC RECLASSIFICATION OF A COHORT OF MEXICAN PATIENTS
por: Collazo, Alfonso Orozco, et al.
Publicado: (2023)

PB1953: TWELVE CASES OF MULTICENTRIC CASTLEMAN DISEASE WITH ELEVATED SERUM IGG4 LEVELS AND INFILTRATING IGG4 POSITIVE PLASMA CELLS PATHOLOGICALLY FROM A SINGLE CENTER.
por: Dai, Shishuo, et al.
Publicado: (2023)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

2708. Infectious Complications Among CD19 Chimeric Antigen Receptor T-cell Recipients
por: Huggins, Jonathan, et al.
Publicado: (2023)

2708. Genetic Structure of Streptococcus pneumoniae Isolated from Invasive Disease in Korea, 2014–2016
por: Kim, Ye Kyung, et al.
Publicado: (2019)

Doxycycline Changes the Transcriptome Profile of mIMCD3 Renal Epithelial Cells
por: Jung, Hyun Jun, et al.
Publicado: (2021)

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
por: Fajgenbaum, David C., et al.
Publicado: (2022)

Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO
por: Phillips, Alexis D., et al.
Publicado: (2022)

PB1776: EXPRESSION OF BCL2, BAX AND MDR1 GENES AS PHARMACOTRANSCRIPTOMIC MARKERS OF PROGNOSIS IN DE NOVO PATIENTS OF ADULT ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE
por: Gašić, Vladimir, et al.
Publicado: (2023)

Expression and Trafficking of the γ Subunit of Na,K-ATPase in Hypertonically Challenged IMCD3 Cells
por: Pihakaski-Maunsbach, Kaarina, et al.
Publicado: (2008)

Unexpected localization of AQP3 and AQP4 induced by migration of primary cultured IMCD cells
por: Rose, Ralph, et al.
Publicado: (2021)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Epoxyeicosatrienoic Acids Attenuating Hypotonic-Induced Apoptosis of IMCD Cells via γ-ENaC Inhibition
por: Wang, Luyun, et al.
Publicado: (2014)

Metabolic Phenotyping of Anks3 Depletion in mIMCD-3 cells - a Putative Nephronophthisis Candidate
por: Schlimpert, Manuel, et al.
Publicado: (2018)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

PB1821: THE INFLUENCE OF BCL2, BAX, BAX/BCL2 RATIO AND MDR1 GENE EXPRESSION ON PROGNOSIS OF ADULT DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
por: Pravdic, Zlatko, et al.
Publicado: (2023)

PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Karan-Đurašević, Teodora, et al.
Publicado: (2023)

PB2506: EVIDENCE OF SPLEEN STIFFNESS PROGRESSION BY TRANSIENT ELASTOGRAPHY IN SCD PATIENTS: RESULTS FROM AN EXPLORATORY STUDY
por: Piolatto, Andrea, et al.
Publicado: (2023)

Comment on: Tessari et al. Roles of Insulin, Age, and Asymmetric Dimethylarginine on Nitric Oxide Synthesis In Vivo. Diabetes 2013;62:2699–2708
por: Kruszelnicka, Olga, et al.
Publicado: (2013)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Response to Comment on: Tessari et al. Roles of Insulin, Age, and Asymmetric Dimethylarginine on Nitric Oxide Synthesis In Vivo. Diabetes 2013;62:2699–2708
por: Tessari, Paolo
Publicado: (2013)

PB2141: CLINICOPATHOLOGICAL FEATURES AND OUTCOME OF CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA AND THE SIGNIFICANCE OF CD5 EXPRESSION STRENGTH: 10-YEAR SINGLE CENTER EXPERIENCE
por: Vukovic, V., et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_628o6csifiank5ial1jhi3icj0